3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
3D Medicines
3D Medicines
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
St. Louis University
University of Miami
M.D. Anderson Cancer Center
Deventer Ziekenhuis
Peking University First Hospital
Henan Cancer Hospital
Washington University School of Medicine
The First Affiliated Hospital with Nanjing Medical University
SWOG Cancer Research Network
Institut du Cancer de Montpellier - Val d'Aurelle
Qianfoshan Hospital
Zhejiang Cancer Hospital
Medlab Clinical
Roswell Park Cancer Institute
Medical University of Lublin
M.D. Anderson Cancer Center
Tetra Bio-Pharma
M.D. Anderson Cancer Center
Taiwan Mundipharma Pharmaceuticals Ltd.
Taiwan Mundipharma Pharmaceuticals Ltd.
Mundipharma (China) Pharmaceutical Co. Ltd
University of Southern California
Mundipharma Korea Ltd
Mundipharma Research GmbH & Co KG
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Mundipharma (China) Pharmaceutical Co. Ltd
Mundipharma Korea Ltd
Mundipharma (China) Pharmaceutical Co. Ltd
Mundipharma Korea Ltd
Mundipharma Research GmbH & Co KG
Mario Negri Institute for Pharmacological Research
Gyeongsang National University Hospital
Fondazione IRCCS Policlinico San Matteo di Pavia
National Cancer Institute (NCI)
Associazione Progetto Oncologia UMAN.A
Akela Pharma, Inc.